Eli Lilly ROA 2010-2022 | LLY

Current and historical return on assets (ROA) values for Eli Lilly (LLY) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Eli Lilly ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-06-30 $5.69B $47.06B 11.92%
2022-03-31 $6.13B $46.92B 12.79%
2021-12-31 $5.58B $48.81B 11.65%
2021-09-30 $5.97B $48.19B 12.61%
2021-06-30 $6.07B $47.81B 13.11%
2021-03-31 $6.09B $46.84B 13.58%
2020-12-31 $6.19B $46.63B 14.27%
2020-09-30 $5.57B $43.95B 13.40%
2020-06-30 $5.62B $41.97B 14.03%
2020-03-31 $5.53B $41.10B 14.10%
2019-12-31 $8.32B $39.29B 21.63%
2019-09-30 $7.95B $37.89B 20.06%
2019-06-30 $7.84B $38.67B 18.99%
2019-03-31 $6.26B $38.01B 14.82%
2018-12-31 $3.23B $43.91B 7.38%
2018-09-30 $0.45B $44.63B 1.02%
2018-06-30 $-0.14B $42.36B -0.33%
2018-03-31 $1.12B $44.36B 2.59%
2017-12-31 $-0.20B $44.98B -0.49%
2017-09-30 $2.23B $43.01B 5.55%
2017-06-30 $2.45B $40.95B 6.32%
2017-03-31 $2.19B $37.62B 5.81%
2016-12-31 $2.74B $38.81B 7.42%
2016-09-30 $2.44B $37.59B 6.77%
2016-06-30 $2.47B $36.48B 6.90%
2016-03-31 $2.32B $34.69B 6.50%
2015-12-31 $2.41B $35.57B 6.71%
2015-09-30 $2.36B $36.31B 6.54%
2015-06-30 $2.06B $36.04B 5.78%
2015-03-31 $2.19B $35.65B 6.20%
2014-12-31 $2.39B $36.31B 6.80%
2014-09-30 $2.69B $34.65B 7.70%
2014-06-30 $3.39B $35.02B 9.76%
2014-03-31 $3.86B $34.76B 11.27%
2013-12-31 $4.68B $35.25B 13.91%
2013-09-30 $4.78B $33.97B 14.29%
2013-06-30 $4.91B $33.23B 14.62%
2013-03-31 $4.63B $32.30B 13.93%
2012-12-31 $4.09B $34.40B 12.32%
2012-09-30 $4.12B $34.32B 12.48%
2012-06-30 $4.03B $31.81B 12.33%
2012-03-31 $4.30B $32.24B 13.06%
2011-12-31 $4.35B $33.66B 13.26%
2011-09-30 $4.66B $33.04B 14.50%
2011-06-30 $4.73B $32.78B 15.08%
2011-03-31 $4.88B $31.70B 16.22%
2010-12-31 $5.07B $31.00B 17.51%
2010-09-30 $4.82B $29.90B 17.15%
2010-06-30 $4.45B $27.72B 16.27%
2010-03-31 $4.26B $27.20B 15.69%
2009-12-31 $4.33B $27.46B 16.02%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $287.922B $28.318B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $447.434B 17.03
Pfizer (PFE) United States $279.310B 8.19
AbbVie (ABBV) United States $247.976B 10.54
Novo Nordisk (NVO) Denmark $236.707B 31.22
Merck (MRK) United States $226.779B 11.84
Novartis AG (NVS) Switzerland $192.828B 14.22